Silence Therapeutics plc (SLN) income statement
SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.82+0.02 (+0.10%)
Close on Nov 18, 2026Market cap $936.43MP/E –Yield –
Silence Therapeutics plc income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 95.0%
- Operating margin
- -12343.6%
- Net margin
- -11276.5%
- Return on equity, FY2025
- -90.3%
Financial strength
- Current ratio
- 23.94
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2199.7%
Valuation
- P/E ratio
- –
- Price to sales
- 2053.57
- Price to book
- 4.36
- Dividend yield
- –
See a number that looks wrong?